Precision BioSciences raises $75 million in stock and warrant offering

Precision BioSciences Inc. (NASDAQ: DTIL) announced it has agreed to sell 10,815,000 shares of common stock and accompanying warrants in an underwritten offering expected to generate approximately $75 million in gross proceeds.

The clinical stage gene editing company will sell the shares and warrants at a combined price of $6.14 per unit. The company also agreed to sell pre-funded warrants to certain investors to purchase up to 1,400,000 shares at $6.139995 per unit, which represents the offering price minus the $0.000005 exercise price for each pre-funded warrant.

Each whole warrant carries an exercise price of $7.25 per share, is exercisable immediately and expires five years from the issuance date. The offering includes participation from new and existing investors, including Aberdeen Investments, Bleichroeder LP, Driehaus Capital Management, Empery Asset Management LP, Lynx1 Capital Management, Octagon Capital, Readout Capital, Sphera Funds Management and Stonepine Capital Management.

The offering is expected to close on or about November 12, 2025, subject to customary closing conditions. Precision intends to use the net proceeds to fund ongoing and planned research and development, working capital and general corporate purposes.

Guggenheim Securities is serving as sole book-running manager for the offering. The securities are being offered through a prospectus supplement dated November 10, 2025, and accompanying prospectus dated June 15, 2023, as part of Precision's effective shelf registration statement.

Durham, North Carolina-based Precision develops gene editing therapies using its proprietary ARCUS platform for genetic and infectious diseases.

You May Also Be Interested In

• Viking Therapeutics plans $400M raise via stock and note offerings
• Runway Growth Finance starts unsecured notes offering on Nasdaq
• Zymeworks completes acquisition of Theravance Biopharma